Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A0VH
|
|||
| Drug Name |
PMID28394193-Compound-50
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
BRISTOL-MYERS SQUIBB COMPANY
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C23H27ClN2O4
|
|||
| Canonical SMILES |
CC1=CC(=C(C2=C1CCN(C2=O)CC3=C(C=C(NC3=O)C)OC)Cl)C(C)C4COC4
|
|||
| InChI |
1S/C23H27ClN2O4/c1-12-7-17(14(3)15-10-30-11-15)21(24)20-16(12)5-6-26(23(20)28)9-18-19(29-4)8-13(2)25-22(18)27/h7-8,14-15H,5-6,9-11H2,1-4H3,(H,25,27)
|
|||
| InChIKey |
ZUDMACKBEPQTPV-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Enhancer of zeste homolog 2 (EZH2) | Target Info | Inhibitor | [1] |
| Target's Patent Info | Enhancer of zeste homolog 2 (EZH2) | Target's Patent Info | [1] | |
| KEGG Pathway | MicroRNAs in cancer | |||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Reactome | PRC2 methylates histones and DNA | |||
| Oxidative Stress Induced Senescence | ||||
| PKMTs methylate histone lysines | ||||
| WikiPathways | Interactome of polycomb repressive complex 2 (PRC2) | |||
| Endoderm Differentiation | ||||
| Integrated Pancreatic Cancer Pathway | ||||
| Histone Modifications | ||||
| Cell Differentiation - meta | ||||
| miRs in Muscle Cell Differentiation | ||||
| miR-targeted genes in muscle cell - TarBase | ||||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | EZH2 inhibitors: a patent review (2014-2016).Expert Opin Ther Pat. 2017 Jul;27(7):797-813. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.